RC
OMED

Randolph Company’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History

Randolph Company’s Portfolio OMED Stock Details OMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-30,150
Closed -$345K – 45
2016
Q3 		$345K Buy
+30,150
New +$351K 0.09% 31

Other funds holding OMED

ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
IHM
Iguana Healthcare Management New York $152M AUM 48.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Randolph Company's OMED Position: Q4 2016 in Review

Randolph Company sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q4 2016, closing a stake of 30,150 shares — an estimated $345K sold.

Randolph Company first reported a position in OMED in Q3 2016 and held it in 1 quarter. The position peaked at $345K in Q3 2016. 86 funds tracked by Wall St. Rank hold OMED as of Q4 2016.

  • Randolph Company reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q4 2016 after selling out during the quarter.
  • Randolph Company sold 30,150 OncoMed Pharmaceuticals, Inc. shares in Q4 2016, an estimated $345K.
  • Randolph Company first reported a position in OncoMed Pharmaceuticals, Inc. in Q3 2016 and held it in 1 quarter.
  • Randolph Company's OncoMed Pharmaceuticals, Inc. position peaked at $345K in Q3 2016.
  • 86 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q4 2016.

Based on Randolph Company's 13F filing for Q4 2016, filed 31 Jan 2017.